However, they included hormone receptor (HR)-negative/HER2-positive and triple-negative breast cancers, and Ki-67 LI is not as effective in predicting prognosis for these subtypes as it is for luminal/HER2-negative breast cancers. This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.